|Orexigen Therapeutics, Inc.|
3344 North Torrey Pines Court
United States - Map
|Industry:||Drug Manufacturers - Other|
|Full Time Employees:||41|
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include Contrave, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic, which has completed Phase II clinical trials. The company has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in the United States, Canada, and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.
|Mr. Michael A. Narachi M.S., M.B.A.,
Chief Exec. Officer, Pres and Director
|Mr. Joseph P. Hagan ,
Acting Chief Financial Officer, Principal Accounting Officer, Chief Bus. Officer and Treasurer
|Ms. Heather D. Turner J.D.,
Sr. VP, Gen. Counsel and Sec.
|Mr. Mark D. Booth ,
Chief Commercial Officer
|Mr. Preston Klassen M.D., M.H.S.,
Head of Global Contrave Program and Sr. VP of Product Devel.
|Amounts are as of 2012-12-30 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|